Novartis Investigative Site

Abilene, Texas 79606-5208

0 studies enrolling now · 9 studies all time

What they study most

Age-Related Macular Degeneration, Branch Retinal Vein Occlusion, Cancer, Central Retinal Vein Occlusion, Diabetic Macular Edema, Exudative Macular Degeneration, Eye Diseases, Leukaemia, Lymphocytic, Chronic, Macular Degeneration, Neovascular Age-elated Macular Degeneration (Wet AMD), Neovascular Age-related Macular Degeneration, Retinal Degeneration

Studies at this site

• Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections — Stopped early
• Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion — Stopped early
• Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion — Stopped early
• Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema — Completed
• Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD — Completed
• Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD — Completed
• Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD) — Completed
• Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia — Stopped early
• Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone — Stopped early